Important Alert for ADMA Biologics, Inc. Investors Regarding Class Action Deadline

Reminder for ADMA Biologics, Inc. Shareholders

The Gross Law Firm is reaching out to those who hold shares in ADMA Biologics, Inc. (NASDAQ: ADMA), especially investors who acquired shares between August 9, 2024, and March 25, 2026. There is an impending deadline for shareholders to participate in a class action lawsuit concerning potential mismanagement and misleading practices by the company.

Class Action Details

The allegations mentioned in the complaint suggest ADMA Biologics possibly engaged in several deceptive behaviors that inflated their stock performance artificially. These accusations include:
1. Undisclosed Related Party Transactions: It is claimed that ADMA entered into transactions that were not fully disclosed to shareholders, which may have compromised the transparency required of public companies.
2. Channel Stuffing Practices: The company is alleged to have employed questionable sales tactics, such as channel stuffing, to make its revenue figures seem more robust than they truly were.
3. Inadequate Internal Controls: The firm argues that ADMA Biologics did not maintain adequate internal mechanisms to ensure legitimate reporting and compliance with regulatory standards, pointing to deficiencies that could mislead investors.

Each of these allegations raises significant concerns regarding the operational integrity of ADMA Biologics during the specified period. Given the serious nature of these claims, the upcoming deadline of August 10, 2026, for registering in the class action is of utmost importance for any affected shareholders.

Next Steps for Investors

Potential plaintiffs are encouraged to connect with The Gross Law Firm to discuss the possibility of becoming lead plaintiffs. Importantly, being appointed as a lead plaintiff is not a prerequisite for participating in any recovery from this case. If you register, you will be added to a monitoring system that provides updates about the class action and the status of your potential claim related to your ADMA shares.

The law firm emphasizes that the registration process incurs no cost and poses no obligation for interested shareholders. Acting swiftly is crucial due to the looming deadline, which could impact your ability to seek recourse over any financial losses incurred due to the alleged misconduct by ADMA Biologics.

Why Choose The Gross Law Firm?

As a nationally recognized class action firm, The Gross Law Firm is dedicated to safeguarding investors' rights. Their mission focuses on addressing and advocating against deceitful corporate practices and ensuring companies are held accountable for their actions. Their commitment extends to not only representing investors in legal proceedings but also educating them about their rights and the implications of such cases.

For additional information or to commence the registration process, affected shareholders can visit the firm’s website via the following link.

In conclusion, it is imperative for any ADMA Biologics investors to stay informed and take proactive steps regarding this class action lawsuit. Your financial interests may depend on your timely action regarding these serious allegations against the company.